Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Advanced Hepatocellular Carcinoma
NCT00361309Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in hepatocellular carcinoma (HCC), sponsored by Massachusetts General Hospital. Primary endpoint: Progression Free Survival at 2 years. Started Apr 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00361309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361309.